Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Dr.Reddy's Apremilast API and finished formulation offerings.

Dr. Reddy's is one of the leading API pharma companies supplying Apremilast API globally, and has led the USDMF filing in September 2016 (Form-B) and June 2017 (Amorphous).

Apremilast, is an anti-inflammatory agent modulating a wide range of inflammatory mediators in psoriasis and psoriatic arthritis. Apremilast is indicated for the treatment of active psoriatic arthritis and moderate to severe plaque psoriasis.

Dr. Reddy's amorphous API has been successfully formulated into drug products by various formulators with successful bioequivalence studies and subsequent dossier filing.

To know more about our offerings , please read the technical sheet on Apremilast by filling the contact from below.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.



Book your slot to
explore our API solutions firsthand!

Schedule a meeting at CPHI China